Virtual Screening of Compounds for the Identification of Potential Drug Candidates Targeting the RACK1 Receptor in Liver Cancer
Abstract
Background: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths globally and the sixth most common cancer, particularly in the Asia-Pacific and African regions. Liver cirrhosis, a critical precursor to HCC and liver failure, necessitates effective treatment options. Although surgical intervention is the current standard, there is a pressing need for novel therapeutics with improved efficacy and reduced side effects. This study focuses on RACK1 (Receptor for Activated C-Kinase 1), a pivotal protein in cancer progression, as a therapeutic target for HCC.
Methods: Protein structures of overexpressed genes in HCC, including RACK1, were retrieved from the Protein Data Bank (PDB). Active binding sites on RACK1 were identified for potential ligand interactions. A library of 12,000 phytochemicals was sourced from PubChem, ZINC, and MP3D databases and screened against RACK1 using the PyRx virtual screening tool. The top candidates were analyzed for pharmacokinetic properties using ADMETsar. Molecular dynamics simulations were conducted to study ligand-receptor interactions and validate the potential drug candidates.
Results: The study identified promising phytochemical compounds (Pubchem11059920, Pubchem118855584, Pubchem3086637, Pubchem442813 and Pubchem88708) capable of binding to RACK1 with high affinity. These compounds exhibited favorable ADMET properties, indicating their potential as drug candidates. Molecular dynamics simulations confirmed stable and significant interactions between the identified ligands and RACK1, supporting their inhibitory potential.
Conclusion: This research highlights RACK1 as a viable therapeutic target for HCC. The identified drug candidates demonstrate potential to inhibit RACK1 function, offering a pathway to suppress HCC progression at its early stages. These findings provide a foundation for the development of effective and targeted treatments for HCC.
Keywords: Hepatocellular carcinoma (HCC), RACK1 receptor, Phytochemical screening, Virtual screening, Molecular dynamics simulation
Full Text:
PDFReferences
Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology, (2010); 51(5): 1820-1832.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: a cancer journal for clinicians, (2018); 68(1): 7-30.
Center MM, Jemal A. International trends in liver cancer incidence rates. Cancer Epidemiology and Prevention Biomarkers, (2011); 20(11): 2362-2368.
Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology, (2004); 127(5): S5-S16.
Liu C-Y, Chen K-F, Chen P-J. Treatment of liver cancer. Cold Spring Harbor perspectives in medicine, (2015); 5(9): a021535.
McCahill A, Warwicker J, Bolger GB, Houslay MD, Yarwood SJ. The RACK1 scaffold protein: a dynamic cog in cell response mechanisms. Molecular pharmacology, (2002); 62(6): 1261-1273.
Adams DR, Ron D, Kiely PA. RACK1, A multifaceted scaffolding protein: Structure and function. Cell communication and signaling, (2011); 9(1): 1-24.
Li J, Xie D. RACK1, a versatile hub in cancer. Oncogene, (2015); 34(15): 1890-1898.
Yoon SY, Kim J-M, Oh J-H, Jeon Y-J, Lee D-S, et al. Gene expression profiling of human HBV-and/or HCV-associated hepatocellular carcinoma cells using expressed sequence tags. International journal of oncology, (2006); 29(2): 315-327.
Guo Y, Wang W, Wang J, Feng J, Wang Q, et al. Receptor for activated C kinase 1 promotes hepatocellular carcinoma growth by enhancing mitogen‐activated protein kinase kinase 7 activity. Hepatology, (2013); 57(1): 140-151.
Ruan Y, Sun L, Hao Y, Wang L, Xu J, et al. Ribosomal RACK1 promotes chemoresistance and growth in human hepatocellular carcinoma. The Journal of clinical investigation, (2012); 122(7): 2554-2566.
Halim SA, Sikandari AG, Khan A, Wadood A, Fatmi MQ, et al. Structure-based virtual screening of tumor necrosis factor-α inhibitors by cheminformatics approaches and bio-molecular simulation. Biomolecules, (2021); 11(2): 329.
Burley SK, Bhikadiya C, Bi C, Bittrich S, Chen L, et al. RCSB Protein Data Bank: powerful new tools for exploring 3D structures of biological macromolecules for basic and applied research and education in fundamental biology, biomedicine, biotechnology, bioengineering and energy sciences. Nucleic acids research, (2021); 49(D1): D437-D451.
Rehman G, Khan S., Iqbal A, Hamayun M, Hussain A, et al. Confirmation of antioxidant and antiangiogenic potential of adult housefly extracts through chick chorioallantoic membrane (cam) assay. FEB FRESENIUS ENVIRONMENTAL BULLETIN,(2020); p.8620.
Muneer I, Ahmad S, Naz A, Abbasi SW, Alblihy A, et al. Discovery of Novel Inhibitors From Medicinal Plants for V-Domain Ig Suppressor of T-Cell Activation. Frontiers in Molecular Biosciences, (2021); 8, p.716735.
Said MA, Albohy A, Abdelrahman MA, Ibrahim HS. Importance of glutamine 189 flexibility in SARS-CoV-2 main protease: Lesson learned from in silico virtual screening of ChEMBL database and molecular dynamics. European Journal of Pharmaceutical Sciences, (2021); 160105744.
Kim S, Chen J, Cheng T, Gindulyte A, He J, et al. PubChem in 2021: new data content and improved web interfaces. Nucleic acids research, (2021); 49(D1): D1388-D1395.
Berge A. and Björck L. Streptococcal Cysteine Proteinase Releases Biologically Active Fragments of Streptococcal Surface Proteins. Journal of Biological Chemistry, (1995); 270(17), pp.9862-9867.
Rehman A, Ashfaq UA, Javed MR, Shahid F, Noor F, et al. The Screening of phytochemicals against NS5 Polymerase to treat Zika Virus infection: Integrated computational based approach. Combinatorial Chemistry & High Throughput Screening, (2022); 25(4), pp.738-751.
Riyadi P, Sari I, Kurniasih R, Agustini T, Swastawati F, et al. SwissADME predictions of pharmacokinetics and drug-likeness properties of small molecules present in Spirulina platensis; 2021. IOP Publishing. pp. 012021.
Snowden FM. Emerging and reemerging diseases: a historical perspective. Immunological reviews, (2008); 225(1): 9-26.
Water S, Organization WH Emerging issues in water and infectious disease. 2002; World Health Organization.
Schneider G, Fechner U. Computer-based de novo design of drug-like molecules. Nature reviews Drug discovery, (2005); 4(8): 649-663.
Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nature reviews Drug discovery, (2004); 3(11): 935-949.
Lengauer T, Rarey M. Computational methods for biomolecular docking. Current opinion in structural biology, (1996); 6(3): 402-406.
Śledź P, Caflisch A. Protein structure-based drug design: from docking to molecular dynamics. Current opinion in structural biology, (2018); 4893-102.
Kuntz ID, Blaney JM, Oatley SJ, Langridge R, Ferrin TE. A geometric approach to macromolecule-ligand interactions. Journal of molecular biology, (1982); 161(2): 269-288.
Wang L, Wu Y, Deng Y, Kim B, Pierce L, et al. Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern free-energy calculation protocol and force field. Journal of the American Chemical Society, (2015); 137(7): 2695-2703.
Zhang M-Q, Wilkinson B. Drug discovery beyond the ‘rule-of-five’. Current opinion in biotechnology, (2007); 18(6): 478-488.
Giménez B, Santos M, Ferrarini M, Fernandes J. Evaluation of blockbuster drugs under the rule-of-five. Die Pharmazie-An International Journal of Pharmaceutical Sciences, (2010); 65(2): 148-152.
Tripathi P, Ghosh S, Talapatra SN. Bioavailability prediction of phytochemicals present in Calotropis procera (Aiton) R. Br. by using Swiss-ADME tool. World Scientific News, (2019); 131147-163.
Alshabrmi FM, Alkhayl FFA, Rehman AJEJoP. Novel Drug Discovery: Advancing Alzheimer's Therapy through Machine Learning and Network Pharmacology, (2024); 176661.
Rehman A, Fatima I, Wang Y, Tong J, Noor F, et al. Unveiling the multi-target compounds of Rhazya stricta: discovery and inhibition of novel target genes for the treatment of clear cell renal cell carcinoma, (2023); 165107424.
Lohohola PO, Mbala BM, Bambi S-MN, Mawete DT, Matondo A, et al. In silico ADME/T properties of quinine derivatives using SwissADME and pkCSM webservers, (2021); 42(11): 1-12.
Rehman A, Noor F, Fatima I, Qasim M, Liao MJCiB, et al. Identification of molecular mechanisms underlying the therapeutic effects of Celosia Cristata on immunoglobulin nephropathy, (2022); 151106290.
Mishra S, Dahima RJJodd, therapeutics. In vitro ADME studies of TUG-891, a GPR-120 inhibitor using SWISS ADME predictor, (2019); 9(2-s): 366-369.
Aloufi B, Alshabrmi FM, Sreeharsha N, Rehman AJJoBS, Dynamics. Exploring therapeutic targets and drug candidates for obesity: a combined network pharmacology, bioinformatics approach, (2023); 1-22.
DOI: http://dx.doi.org/10.62940/als.v12i1.3617
Refbacks
- There are currently no refbacks.